Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
28 hedge funds and large institutions have $225M invested in Sinovac Biotech, Ltd in 2026 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 2 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 2
0% more funds holding
Funds holding: 28 → 28 (0)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% less capital invested
Capital invested by funds: $225M → $225M (-$406K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HI
Harbour Investments
Madison,
Wisconsin
|
+$542 |
| 2 |
HI
Horizon Investments
Charlotte,
North Carolina
|
+$337 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AWM
Aprio Wealth Management
Atlanta,
Georgia
|
-$284K |
| 2 |
Wells Fargo
San Francisco,
California
|
-$78.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$45.2K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
1
OrbiMed
New York
| $184M | – | – | – |
|
|
VC
2
Vivo Capital
Palo Alto,
California
| $38.2M | – | – | – |
|
|
NAH
3
Neumann Advisory (HK)
Central,
Hong Kong
| $2.04M | – | – | – |
|
4
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $106K | – | – | – |
|
5
Morgan Stanley
New York
| $59.2K | – | – | – |
|
|
6
Wells Fargo
San Francisco,
California
| $31.1K | -$78.1K | -12,065 | -71% |
|
|
7
UBS Group
Zurich,
Switzerland
| $14.4K | -$45.2K | -6,993 | -76% |
|
|
HI
8
Horizon Investments
Charlotte,
North Carolina
| $673 | +$337 | +52 | +100% |
|
|
HI
9
Harbour Investments
Madison,
Wisconsin
| $542 | +$542 | +83 | New |
|
|
AWM
10
Aprio Wealth Management
Atlanta,
Georgia
| – | -$284K | -439 | Closed |
|
SVA Hedge Fund Activity: Q1 2026 in Review
28 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q1 2026, worth a combined $225M — down 0.18% from $225M a quarter earlier.
Fund positioning in SVA was balanced in Q1 2026: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 2 trimmed.
The largest buyer was Harbour Investments, opening a new position worth an estimated $542. The largest seller was Aprio Wealth Management, exiting entirely with an estimated $284K sold.
- 28 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q1 2026, unchanged from Q4 2025.
- Funds reported $225M of Sinovac Biotech, Ltd stock for Q1 2026, down 0.18% quarter-over-quarter.
- 3 funds opened new Sinovac Biotech, Ltd positions in Q1 2026 and 3 closed out, a net change of 0 holders.
- The largest Sinovac Biotech, Ltd buyer in Q1 2026 was Harbour Investments, an estimated $542 added.
- The largest Sinovac Biotech, Ltd seller in Q1 2026 was Aprio Wealth Management, an estimated $284K sold.
Based on aggregated 13F filings for Q1 2026.